Severe acute local reactions to a hyaluronic acid-derived dermal filler

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 5, 2010, Pages

  van Dyke, Susan ^a   Hays, Geoffrey P ^b   Caglia, Anthony E ^c   Caglia, Michael ^d  

^a Van Dyke Laser and Skin   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c Derm Aesthetics and Laser Center   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; COTRIMOXAZOLE; ELEVESS; FILLER; HYALURONIC ACID; HYALURONIC ACID INJECTABLE FILLER; HYALURONIDASE; IBUPROFEN; JUVEDERM; JUVEDERM ULTRA PLUS; LEVOFLOXACIN; LIDOCAINE; METHYLPREDNISOLONE; MINOCYCLINE; PREDNISONE; STEROID; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ANTIBIOTIC THERAPY; ARTICLE; ASPIRATION; BACTERIUM CULTURE; CASE REPORT; CELLULITIS; CHEILITIS; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MIXTURE; DRUG TREATMENT FAILURE; ENZYMATIC DEGRADATION; ERYTHEMA; FEMALE; GRAM STAINING; HUMAN; INCISION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE SWELLING; PAIN; PATIENT SATISFACTION; PURPURA; RECURRENT DISEASE; SKIN DISCOLORATION; SKIN TEMPERATURE; SWELLING; TREATMENT OUTCOME;

EID: 77954257354     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Andre P, Lowe N, Parc A, Clerici T, Zimmermann U. Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther. 2005;7:171-176.
2. Bachmann F, Erdmann R, Hartmann V, Wiest L, Rzany B. The spectrum of adverse reactions after treatment with injectable filler in the glabellar region: results from the injectable filler safety study. Dermatol Surg. 2009;35:1629-1634.
3. Glaich AS, Cohen JL, Goldberg LH. Injection necrosis of the glabella: protocol for prevention and treatment after use of dermal fillers. Dermatol Surg. 2006;32(2):276-281.
4. Rossner F, Rossner M, Hartmann V, et al. Decrease of reported adverse events of injectable polylactic acid after recommending an increased dilution: 8-year results from the Injectable Filler Safety Study. J Cosmet Dermatol. 2009;8(1):14-18.
5. Friedman PM, Mafong EA, Kauvar ANB, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg. 2002;28(6):491-494.
6. United States Food and Drug Administration. Center for Devices and Radiological Health. Office of Device Education. Executive Summary-Dermal Filler Devices. GPO 2008.
7. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg. 2005;31(11):1616-1625.
8. Zielke H, Wolber L, Wiest L, Rzany B. Risk profiles of different injectable fillers: results from the injectable filler safety study (IFS Study). Dermatol Surg. 2008;34(3):326-335.
9. DeLorenzi C, Weinberg M, Solish N, Swift A. The long-term efficacy and safety of subcutaneously injected large-particle stabilized hyaluronic acid-based gel of non-animal origin in esthetic facial contouring. Dermatol Surg. 2009;35:313-321.
10. Alam M, Gladstone H, Kramer E, et al. ASDS Guidelines of Care: Injectable Fillers. Dermatol Surg. 2008;34:S115-S148.
11. Beljaards RC, de Roos KP, Bruins FG. NewFill for skin augmentation: a new filler or failure? Dermatol Surg. 2005;31(7):772-776.
12. Lupton JR, Alster TS. Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg. 2000;26(2):135-137.
13. Rzany B, Becker-Wegerich P, Bachmann F, et al. Hyaluronidase in the correction of hyaluronic acid-based fillers: a review and a recommendation for use. J Cosmet Dermatol. 2009;8(4):317-323.
14. Andre P, Flechet ML. Angioedema after ovine hyaluronidase injection for treating hyaluronic acid overcorrection. J Cosmet Dermatol. 2008;7:136-138.
15. Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable non-animal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg. 2002;28:491-494.